Denali CEO makes 32,220-share charitable stock gift

Denali Therapeutics Inc. President and CEO Ryan J. Watts reported a bona fide gift of 32,220 shares of Denali common stock on August 12, 2026.

Rhea-AI Filing Summary

Denali Therapeutics Inc. President and CEO Ryan J. Watts reported a bona fide gift of 32,220 shares of Denali common stock on August 12, 2026. The in-kind charitable contribution was made to a donor advised fund from shares held indirectly through the Watts Family 2015 Trust, for which he serves as trustee. After the transactions, he reports 2,120,384 indirect shares and 296,833 direct shares, including 184,915 unvested RSUs.

Insider Trade Summary

32,220 shares gifted

Gift 2 txns

Insider Watts Ryan J.

Role President and CEO

Type	Security	Shares	Price	Value
Gift	Common Stock F1, F2	32,220	$0.00	$0.00
holding	Common Stock F3	--	--	--

Holdings After Transaction: Common Stock — 2,120,384 shares (Indirect, See footnote); Common Stock — 296,833 shares (Direct)

Footnotes (3)

1. F1. Reflects an in-kind charitable contribution of 32,220 shares of DNLI to a donor advised fund.
2. F2. The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
3. F3. Includes 184,915 unvested RSUs.

Key Figures

Shares gifted: 32,220 shares Indirect holdings after transaction: 2,120,384 shares Direct holdings after transaction: 296,833 shares +2 more

5 metrics

Shares gifted 32,220 shares In-kind charitable contribution to a donor advised fund on August 12, 2026

Indirect holdings after transaction 2,120,384 shares Common stock held indirectly after the gift, via Watts Family 2015 Trust

Direct holdings after transaction 296,833 shares Common stock held directly by Ryan J. Watts following the reported transactions

Unvested RSUs included in direct holdings 184,915 RSUs Portion of direct position represented by unvested restricted stock units

Gift price per share $0.0000 per share Reported transaction price for the bona fide gift of common stock

Key Terms

bona fide gift, donor advised fund, unvested RSUs, indirect ownership

4 terms

bona fide gift financial

"The transaction code G is described as a bona fide gift."

A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.

donor advised fund financial

"An in-kind charitable contribution of 32,220 shares of DNLI to a donor advised fund."

A donor advised fund is a charitable savings account you fund with cash or assets (including stocks) that lets you take an immediate tax benefit while recommending when and which charities receive grants over time. Think of it like a dedicated piggy bank for giving: you get tax relief when you put money in, can avoid selling appreciated securities and triggering capital gains, and still control the timing and recipients of donations, which affects tax planning, portfolio decisions, and public giving signals.

unvested RSUs financial

"Includes 184,915 unvested RSUs."

indirect ownership financial

"The shares are held of record by the Watts Family 2015 Trust, indicating indirect ownership."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Denali Therapeutics (DNLI) CEO Ryan Watts report in this Form 4?

Ryan J. Watts reported a bona fide gift of 32,220 DNLI shares on August 12, 2026. The in-kind contribution went from a trust he oversees to a donor advised fund, with no sale proceeds reported.

How many Denali Therapeutics (DNLI) shares did Ryan Watts donate?

Ryan Watts donated 32,220 shares of Denali Therapeutics common stock. The filing describes this as an in-kind charitable contribution of DNLI shares to a donor advised fund from trust-held shares.

From which account were the donated DNLI shares transferred?

The 32,220 DNLI shares were transferred from the Watts Family 2015 Trust. The trust holds the shares of record, and Ryan J. Watts serves as trustee, so the transaction is reported as indirect ownership on the Form 4.

What are Ryan Watts’ remaining DNLI holdings after this Form 4 transaction?

After the reported transactions, Ryan Watts reports 2,120,384 indirectly held DNLI shares and 296,833 directly held shares. The direct holdings figure includes 184,915 unvested RSUs, as disclosed in the footnotes.

Does the Form 4 indicate any sale of DNLI shares by Ryan Watts?

The Form 4 does not report any sales; it reports a bona fide gift of 32,220 DNLI shares. The transaction code is G, which the filing describes as a charitable gift to a donor advised fund at no stated price.

Are unvested RSUs included in Ryan Watts’ reported DNLI holdings?

Yes. The filing states his 296,833 directly held DNLI shares include 184,915 unvested RSUs. This means a substantial portion of his direct position consists of restricted stock units that have not yet vested.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 04:48 PM Accepted by SEC EDGAR 08/14/2026 - 04:48 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Watts Ryan J.

(Last) (First) (Middle)

C/O DENALI THERAPEUTICS INC.

161 OYSTER POINT BLVD.

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Denali Therapeutics Inc. [ DNLI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2026		G		32,220(1)	D	$0	2,120,384	I	See footnote(2)
Common Stock								296,833(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects an in-kind charitable contribution of 32,220 shares of DNLI to a donor advised fund.

2. The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.

3. Includes 184,915 unvested RSUs.

Remarks:

	/s/ Tyler Nielsen, by power of attorney	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)